Dissemination
• Scientific Presentations
• Scientific Publications
Scientific Presentations
several presentations were held at the:
XLVII ERA-EDTA Congress
II DGfN Congress
Muinich, Germany, June 25-28
http://www.eraedta2010.org/sprogram.htm
GWAS and renal outcomes
Rainer Oberbauer, Linz, Austria
Transcriptional profiling in nephrology
Gert Mayer, Innsbruck, Austria
Proteome analysis in the assessment of renal disease
Harald Mischak, Hannover, Germany
Integration of large scale data sets in renal disease: genetics-genomics-metabolomics
Matthias Kretzler, Ann Arbor, USA
Approaches for linking the Omics levels
Bernd Mayer, Vienna, Austria
Standard versus intensified dialysis in AKI in intensive care units
Danilo Fliser, Homburg/Saar, Germany
ERA-EDTA Registry
Vianda Stel, Amsterdam, The Netherlands
The complementary use of Registry data for research into rare diseases
Cardiovascular risk biomarkers
Biomarkers: when is it justified to incorporate a new biomarker into clinical practice?
Carmine Zoccali, Reggio Calabria, Italy
Protein bound uremic toxins
Joachim Jankowski, Berlin, Germany
The bone (adipocyte) vascular axis
Beyond Ca/P/PTH: clinical evidence of a link between the adipose tissue and bone disease in ESRD
Andrzej Wiecek, Katowice, Poland
Haemodialysis
Biocompatibility and genomics in dialysis
Rainer Oberbauer, Linz, Austria
European Cardiovascular and Renal Medicine (EURECAM)
EURECAM mission and results of surveys
Carmine Zoccali, Reggio Calabria, Italy
Potential and caveats on the use of Clinical Trials data-bases for secondary analyses in Cardiovascular and Renal Medicine
Johannes Mann, Munich, Germany
ERA-EDTA Nephroquest Working Group
NephroQUEST - different tools to improve the quality of RRT care
K. J. Jager, Amsterdam, The Netherlands
Immune mechanisms in autoimmune nephritis
Novel roles of chemokines
Carla Zoja, Bergamo, Italy
Progression of renal damage
Capillary rarefication, angiogenesis and VEGF in the progression of renal disease
Gert Mayer, Innsbruck, Austria
Growth factors in renal regeneration
Josep M. Cruzado, Barcelona, Spain
Prevention of cardiovascular risk in renal patients
Effect of blood pressure lowering on cardiovascular morbidity and mortality in people with chronic kidney disease
Hiddo J. Lambers Heerspink, Groningen, The Netherlands
Practices in renal transplantation
Cardiovascular screening of potential transplant recipients
Alan G. Jardine, Glasgow, UK
"SME success story in FP7, SYSKID"
Presenter: Bernd Mayer, Vienna, Austria
Meeting: FP7 Health - Open Information Day & Brokerage event
Brussels, Belgium, June 8 2010
Webcast available here
Scientific Publications
EU Projekt SysKid – Systems Biology towards Novel Chronic Kidney Disease Diagnosis and Treatment
NEPHRO-NEWS - 3/10
Alexander Kainz, Gert Mayer, Rainer Oberbauer, Bernd Mayer
Urinary proteomics
Harald Mischak, Petra Zürbig
A manuscript entitled “Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease” is now online available on the MCP homepage
This manuscript describes the generation of a urinary proteomic biomarker pattern specific for chronic kidney diseases (CKD). Application of the CKD-specific biomarker set to an independent test cohort in the subsequent replication phase resulted in 85.5% sensitivity and 100% specificity. Due to the fact that CKD is frequently associated with underlying pathologies like diabetes, hypertension, or chronic viral infection, further patients with other diseases than CKD were included. The classification of these “diseased controls” resulted in an overall specificity of 97.8%. One of the hallmarks of CKD appears to be the accumulation of extracellular matrix (ECM) and the release of its components, most notably collagen. All these findings demonstrate that this process is in part caused by reduced proteolysis and is reflected at a very early stage by a decrease in urinary collagen fragments.
This CKD-specific biomarker model also enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria (Andersen et al. 2010, submitted). Therapy with 300 mg daily doses of Irbesartan over a period of two years resulted in significant changes of the urinary proteome. Both, the CKD model as well as several individual peptides changed significantly after treatment. These changes were not observed in the placebo-treated individuals. The CKD biomarker pattern furthermore facilitates detection of DN at a very early stage, several years prior to microalbuminuria (Mischak et al. Nephrol. Dial. Transplant., Advance Access published on June 22, 2010). This opens the avenue towards early, targeted therapeutic intervention.
"Data Annotation and Relations Modeling for Integrated Omics in Clinical Research"
A. Lukas and B. Mayer,
IIOABJ, 2010; Vol.1 (2): 15-23
Read abstract
"Plasma growth differentiation factor-15 (GDF-15) independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy"
Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P
Diabetes Care July 2010 vol. 33 no. 7 1567-1572
Read abstract
